Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics

Júnior, Roberto Clayton Lima Oliveira; Pereira, Marcelo Glauber da Silva; Garcia, Pedro Braga Linhares; Santos, Patrícia Albuquerque dos; Cavalcanti, Amanda dos Santos; Meohas, Walter

doi:10.1016/j.rboe.2016.06.004

Cited by 9 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported that the incidence of lung metastasis in benign giant cell tumours was approximately 3.5% [14,15], while it was approximately 8% in malignant cases [16,17]. In our study, 14 out of 89 cases extracted from 2010 to 2016 were recorded as M1 status, and the lung was the major metastatic site (10 out of 89 cases, 11.2%).…”

Section: Discussionmentioning

confidence: 50%

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (HR=9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

show abstract

Section: Discussionmentioning

confidence: 50%

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Compared with the 5-year OS of 81.3% for patients without metastasis, that of patients with metastasis significantly decreased to 53.9%. Previous studies reported that the incidence of lung metastasis in benign giant cell tumours was approximately 3.5% [14,15], while it was approximately 8% in malignant cases [16,17]. In our study, 14 out of 89 cases extracted from 2010 to 2016 were recorded as M1 status, and the lung was the major metastatic site (10 out of 89 cases, 11.2%).…”

Section: Discussionmentioning

confidence: 50%

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Zhang¹,

Wang

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (hazard ratio (HR) =9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

show abstract

“…Compared with the 5-year OS of 81.3% for patients without metastasis, it significantly decreased to 53.9 % for those with metastasis. Previous studies reported that the incidence of lung metastasis in benign giant cell tumor was around 3.5% [13,14] while approximately 8% in the malignant cases [15,16]. In our study, 14 out of 89 cases extracted from 2010 to 2016 were recorded as M1 status and lung was the major metastatic site (10 out of 89, 11.2%).…”

Section: Discussionmentioning

confidence: 54%

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Zhang¹,

Wang

Li³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background The characteristics and survival in patients with malignant giant tumor cancer of bone (GCTB) were not investigated thoroughly due to the limited population. We evaluated the issues based on a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods Patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis and the inter-group difference was tested by log-rank test. Univariate and multivariate Cox proportional hazard regression were conducted to identify the independent survival factors. Results A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. In the univariate analysis, age older than 34 years, grade IV, T2/3 stage, M1, distant and surgery of the primary site. Multivariate Cox regression showed the poor survival in patients with age older than 34 years (hazard ratio (HR) =3.68, 95% CI: 2.06-6.57, P<0.001), T2 stage (HR=4.96, 95% CI: 1.57-15.63, P=0.006), distant tumor (HR=3.02, 95% CI: 1.32-6.92, P=0.009), and the extra-skeletal sites (HR=8.84, 95% CI: 2.89-27.07, P<0.001), respectively. Conclusions This large population-based series described the clinical characteristics of the malignant GCTB. Age, T2, distant tumor and extra-skeletal sites were determinant survival factors of the patients with malignant GCTB.

show abstract

Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics

Cited by 9 publications

References 15 publications

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Contact Info

Product

Resources

About